Metabolic switching of human skeletal muscle cells in vitro

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 227-234

  Thoresen, G H ^a   Hessvik, N P ^a   Bakke, S S ^a   Aas, V ^b   Rustan, A C ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; GLUCOSE; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LIVER X RECEPTOR; OLEIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; CELL ACTIVITY; CELL METABOLISM; CONCENTRATION (PARAMETERS); ENERGY METABOLISM; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; LIPID OXIDATION; METABOLIC CAPACITY; METABOLIC REGULATION; METABOLIC SWITCHING; METABOLISM; MICROBIAL RESPIRATION; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

CHRONIC DISEASE; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HUMANS; HYPERGLYCEMIA; LIPID METABOLISM; MUSCLE FIBERS, SKELETAL; ORPHAN NUCLEAR RECEPTORS; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 80053603692     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.017     Document Type: Article

References (81)

1. Rasmussen B.B., Holmback U.C., Volpi E., Morio-Liondore B., Paddon-Jones D., Wolfe R.R. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J. Clin. Invest. 2002, 110:1687-1693.
2. Andres R., Cader G., Zierler K.L. The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state; measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm. J. Clin. Invest. 1956, 35:671-682.
3. Kelley D.E., Reilly J.P., Veneman T., Mandarino L.J. Effects of insulin on skeletal muscle glucose storage, oxidation, and glycolysis in humans. Am. J. Physiol. 1990, 258:E923-E929.
4. Kelley D.E. Skeletal muscle fat oxidation: timing and flexibility are everything. J. Clin. Invest. 2005, 115:1699-1702.
5. Kelley D.E., Mandarino L.J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000, 49:677-683.
6. Blaak E.E., van Aggel-Leijssen D.P., Wagenmakers A.J., Saris W.H., van Baak M.A. Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes 2000, 49:2102-2107.
7. Corpeleijn E., Mensink M., Kooi M.E., Roekaerts P.M., Saris W.H., Blaak E.E. Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss. Obesity (Silver Spring) 2008, 16:1025-1032.
8. Mensink M., Blaak E.E., van Baak M.A., Wagenmakers A.J., Saris W.H. Plasma free Fatty Acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 2001, 50:2548-2554.
9. Galgani J.E., Moro C., Ravussin E. Metabolic flexibility and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1009-E1017.
10. Kelley D.E., Goodpaster B., Wing R.R., Simoneau J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 1999, 277:E1130-E1141.
11. Galgani J.E., Heilbronn L.K., Azuma K., et al. Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate. Diabetes 2008, 57:841-845.
12. Wohl P., Girman P., Pelikanova T. Inflexibility of energy substrate oxidation in type 1 diabetic patients. Metabolism 2004, 53:655-659.
13. Stull A.J., Galgani J.E., Johnson W.D., Cefalu W.T. The contribution of race and diabetes status to metabolic flexibility in humans. Metabolism 2010, 59:1358-1364.
14. Corpeleijn E., Saris W.H., Blaak E.E. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obesity Rev. 2009, 10:178-193.
15. Kelley D.E., Simoneau J.A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1994, 94:2349-2356.
16. Ukropcova B., McNeil M., Sereda O., et al. Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor. J. Clin. Invest. 2005, 115:1934-1941.
17. Goodpaster B.H., Katsiaras A., Kelley D.E. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 2003, 52:2191-2197.
18. Sial S., Coggan A.R., Hickner R.C., Klein S. Training-induced alterations in fat and carbohydrate metabolism during exercise in elderly subjects. Am. J. Physiol. 1998, 274:E785-E790.
19. Gan S.K., Kriketos A.D., Ellis B.A., Thompson C.H., Kraegen E.W., Chisholm D.J. Changes in aerobic capacity and visceral fat but not myocyte lipid levels predict increased insulin action after exercise in overweight and obese men. Diabetes Care 2003, 26:1706-1713.
20. van Hees A.M., Saris W.H., Hul G.B., et al. Effects of dietary fat modification on skeletal muscle fatty acid handling in the metabolic syndrome. Int. J. Obesity (Lond.) 2010, 34:859-870.
21. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
22. Sidossis L.S., Stuart C.A., Shulman G.I., Lopaschuk G.D., Wolfe R.R. Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. J. Clin. Invest. 1996, 98:2244-2250.
23. Sidossis L.S., Wolfe R.R. Glucose and insulin-induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am. J. Physiol. 1996, 270:E733-E738.
24. Hessvik N.P., Bakke S.S., Fredriksson K., et al. Metabolic switching of human myotubes is improved by n-3 fatty acids. J. Lipid Res. 2010, 51:2090-2104.
25. Gaster M., Kristensen S.R., Beck-Nielsen H., Schroder H.D. A cellular model system of differentiated human myotubes. APMIS 2001, 109:735-744.
26. Aas V., Hessvik N.P., Wettergreen M., et al. Chronic hyperglycaemia reduces substrate oxidation and impairs metabolic switching of human myotubes. BBA Molecular Basis of Disease 2011, 1812:94-105.
27. Wensaas A.J., Rustan A.C., Just M., Berge R.K., Drevon C.A., Gaster M. Fatty acid incubation of myotubes from humans with type 2 diabetes leads to enhanced release of beta-oxidation products because of impaired fatty acid oxidation: effects of tetradecylthioacetic acid and eicosapentaenoic acid. Diabetes 2009, 58:527-535.
28. Aas V., Kase E.T., Solberg R., Jensen J., Rustan A.C. Chronic hyperglycaemia promotes lipogenesis and triacylglycerol accumulation in human skeletal muscle cells. Diabetologia 2004, 47:1452-1461.
29. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA 1993, 90:2160-2164.
30. Krey G., Keller H., Mahfoudi A., et al. Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J. Steroid Biochem. Mol. Biol. 1993, 47:65-73.
31. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10:355-361.
32. Lee S.S., Pineau T., Drago J., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 1995, 15:3012-3022.
33. Reddy J.K., Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21:193-230.
34. Muoio D.M., Way J.M., Tanner C.J., et al. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002, 51:901-909.
35. Barak Y., Nelson M.C., Ong E.S., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
36. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999, 42:1033-1049.
37. Spiegelman B.M., Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87:377-389.
38. Muoio D.M., MacLean P.S., Lang D.B., et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J. Biol. Chem. 2002, 277:26089-26097.
39. Tanaka T., Yamamoto J., Iwasaki S., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA 2003, 100:15924-15929.
40. Wang Y.X., Lee C.H., Tiep S., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
41. Berge R.K., Tronstad K.J., Berge K., et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 2005, 87:15-20.
42. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol. Res. 2007, 56:91-98.
43. Madsen L., Guerre-Millo M., Flindt E.N., et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J. Lipid Res. 2002, 43:742-750.
44. Totland G.K., Madsen L., Klementsen B., et al. Proliferation of mitochondria and gene expression of carnitine palmitoyltransferase and fatty acyl-CoA oxidase in rat skeletal muscle, heart and liver by hypolipidemic fatty acids. Biol. Cell 2000, 92:317-329.
45. Berge K., Tronstad K.J., Flindt E.N., et al. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 2001, 22:1747-1755.
46. Westergaard M., Henningsen J., Svendsen M.L., et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 2001, 116:702-712.
47. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 1999, 96:7473-7478.
48. Dressel U., Allen T.L., Pippal J.B., Rohde P.R., Lau P., Muscat G.E. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 2003, 17:2477-2493.
49. Løvås K., Rost T.H., Skorve J., et al. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes Obesity Metab. 2009, 11:304-314.
50. Schultz J.R., Tu H., Luk A., et al. Role of LXRs in control of lipogenesis. Genes. Dev. 2000, 14:2831-2838.
51. Alberti S., Schuster G., Parini P., et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 2001, 107:565-573.
52. Peet D.J., Turley S.D., Ma W., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
53. Cao G., Liang Y., Broderick C.L., et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 2003, 278:1131-1136.
54. Laffitte B.A., Chao L.C., Li J., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 2003, 100:5419-5424.
55. Kase E.T., Thoresen G.H., Westerlund S., Hojlund K., Rustan A.C., Gaster M. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 2007, 50:2171-2180.
56. Kase E.T., Wensaas A.J., Aas V., et al. Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 2005, 54:1108-1115.
57. Turner N., Bruce C.R., Beale S.M., et al. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007, 56:2085-2092.
58. Garcia-Roves P., Huss J.M., Han D.H., et al. Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle. Proc. Natl. Acad. Sci. U SA 2007, 104:10709-10713.
59. Helge J.W., Kiens B. Muscle enzyme activity in humans: role of substrate availability and training. Am. J. Physiol. 1997, 272:R1620-R1624.
60. Ehrenborg E., Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev. 2009, 61:373-393.
61. Wensaas A.J., Rustan A.C., Lovstedt K., et al. Cell-based multiwell assays for the detection of substrate accumulation and oxidation. J. Lipid Res. 2007, 48:961-967.
62. Ciocoiu C.C., Nikolic N., Nguyen H.H., Thoresen G.H., Aasen A.J., Hansen T.V. Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516. Eur. J. Med. Chem. 2010, 45:3047-3055.
63. Xu H.E., Lambert M.H., Montana V.G., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 1999, 3:397-403.
64. Krey G., Braissant O., L'Horset F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997, 11:779-791.
65. Szendroedi J., Roden M. Ectopic lipids and organ function. Curr. Opinion Lipidol. 2009, 20:50-56.
66. Borkman M., Storlien L.H., Pan D.A., Jenkins A.B., Chisholm D.J., Campbell L.V. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N. Engl. J. Med. 1993, 328:238-244.
67. Ellis B.A., Poynten A., Lowy A.J., et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E554-E560.
68. Pan D.A., Lillioja S., Kriketos A.D., et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997, 46:983-988.
69. Itani S.I., Ruderman N.B., Schmieder F., Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51:2005-2011.
70. Manco M., Mingrone G., Greco A.V., et al. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism 2000, 49:220-224.
71. Aas V., Rokling-Andersen M.H., Kase E.T., Thoresen G.H., Rustan A.C. Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells. J. Lipid Res. 2006, 47:366-374.
72. Anderson B.M., Ma D.W. Are all n-3 polyunsaturated fatty acids created equal?. Lipids Health Dis. 2009, 8:33.
73. Duplus E., Forest C. Is there a single mechanism for fatty acid regulation of gene transcription?. Biochem. Pharmacol. 2002, 64:893-901.
74. Chapkin R.S., McMurray D.N., Davidson L.A., Patil B.S., Fan Y.Y., Lupton J.R. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr. 2008, 100:1152-1157.
75. Ma D.W., Seo J., Switzer K.C., et al. n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J. Nutr. Biochem. 2004, 15:700-706.
76. Hulbert A.J. Life, death and membrane bilayers. J. Exp. Biol. 2003, 206:2303-2311.
77. Hulbert A.J., Else P.L. Mechanisms underlying the cost of living in animals. Annu. Rev. Physiol. 2000, 62:207-235.
78. Hulbert A.J., Else P.L. Membranes as possible pacemakers of metabolism. J. Theor. Biol. 1999, 199:257-274.
79. Hulbert A.J., Turner N., Storlien L.H., Else P.L. Dietary fats and membrane function: implications for metabolism and disease. Biol. Rev. Cambridge Philos. Soc. 2005, 80:155-169.
80. Gao C.L., Zhu C., Zhao Y.P., et al. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes. Mol. Cell. Endocrinol. 2010, 320:25-33.
81. Kraegen E.W., Saha A.K., Preston E., et al. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E471-E479.